Why Most People’s Vitamin D Supplementation Is Dosed Wrong

Most vitamin D supplementation goes wrong in one of three ways: a standard dose is applied to everyone regardless of baseline blood level or body size, high doses are taken in infrequent bursts, or megadoses are used as a health strategy by people who are already sufficient.

Matching the dose to measured status, weight and purpose works better.

The vitamin itself is not the problem. Vitamin D is essential for calcium absorption and bone health, and deficiency is real and common.

The problem is how the number on the bottle gets chosen: by habit, by social media consensus, or by the assumption that a higher dose means more protection. Large randomized trials over the past several years have undercut that assumption.

There Is No Universal Dose

The official reference points are modest. The recommended daily allowance is 600 IU for adults up to age 70 and 800 IU after that, with a tolerable upper intake level of 4,000 IU.

Shelves in pharmacies and online stores tell a different story, with 5,000 and 10,000 IU softgels sold as routine daily products.

The Endocrine Society’s 2024 guideline, led by Marie Demay of Massachusetts General Hospital, moved in the opposite direction from that market.

It advises against routine supplementation above the dietary reference intake in healthy adults under 75, and it recommends empiric supplementation only for children, pregnant people, adults 75 and older, and adults with high-risk prediabetes. The panel defined “empiric supplementation” as intake above the reference level without a blood test.

The guideline also dropped the long-standing 30 ng/mL target. The Endocrine Society no longer endorses specific 25-hydroxyvitamin D cutoffs for sufficiency, insufficiency, or deficiency because trials have not linked distinct blood thresholds to clinical outcomes.

This is why many clinicians now report that insurers deny coverage for routine 25(OH)D screening in people with no indication.

What the Large Trials Found

The VITAL trial, led by JoAnn Manson at Brigham and Women’s Hospital, randomized 25,871 initially healthy adults to 2,000 IU of vitamin D3 daily or placebo for a median of 5.3 years.

Vitamin D did not significantly reduce invasive cancer (793 cases versus 824) or major cardiovascular events. A signal for lower cancer mortality appeared after the early follow-up years were excluded, and the investigators described it as needing confirmation.

The D2d trial, led by Anastassios Pittas of Tufts Medical Center, gave 4,000 IU daily to 2,423 adults with prediabetes. The hazard ratio for progression to diabetes was 0.88, which was not statistically significant.

Participants averaged about 28 ng/mL at baseline, so most were not deficient. In the small subgroup below 12 ng/mL, supplementation appeared to help, but the investigators stated that no conclusion could be drawn from so few participants.

These results are easy to misread in both directions. They show that extra vitamin D does not reliably prevent cancer, heart disease or diabetes in people who already have adequate levels. They do not show that correcting a true deficiency is pointless.

Both trials also allowed participants to keep taking background vitamin D from other sources (up to 800 IU in VITAL and 1,000 IU in D2d), which blurs the contrast between treatment and placebo. Researchers who favor higher targets make this argument, and it is a fair one.

The Overdose Risk Is Quieter Than Toxicity

Frank vitamin D toxicity requires enormous exposure. Published cases typically involve labeling errors with doses in the hundreds of thousands of IU per day, or years of self-prescribed megadosing.

One case report described acute kidney injury in a man who had taken 10,000 IU daily for many years while living with chronic kidney disease, with a 25(OH)D level above 100 ng/mL.

Use of 4,000 IU or more per day among US adults rose from under 0.1 percent before 2005 to about 3.2 percent by 2013 and 2014, so the population exposed to this risk is growing.

The more relevant concern for ordinary users is subtler. In a Calgary trial led by Lauren Burt, published in JAMA in 2019, 311 healthy adults with adequate baseline levels took 400, 4,000 or 10,000 IU daily for three years.

Radial bone mineral density fell more in both higher-dose groups than in the 400 IU group, and tibial density fell more at 10,000 IU. Bone strength estimates did not differ significantly, and a follow-up analysis found the density losses were larger in women than in men.

This was a single-center study using imaging measures rather than fracture outcomes, so it is a caution, not a verdict. It does remove the comfortable assumption that more is at worst harmless.

Why Bursts Are Worse Than Daily Dosing

Intermittent megadoses are popular because they are convenient. The evidence for them is poor. In an Australian trial led by Kerrie Sanders, 2,256 women aged 70 and older received either 500,000 IU of vitamin D3 once a year or placebo.

The vitamin D group had 15 percent more falls and 26 percent more fractures, with the excess concentrated in the three months after each dose. The trial used the largest annual dose in any major randomized study, and the mechanism remains unexplained.

The 2024 guideline reflects this, suggesting daily lower-dose vitamin D rather than intermittent high doses for adults 50 and older who have an indication for supplementation.

The wording is a suggestion grounded in limited evidence, and clinicians still prescribe weekly regimens to correct deficiency. Even so, a monthly or annual megadose chosen for convenience in a person without deficiency has the weakest justification of any regimen.

Body Size Changes the Arithmetic

A fixed dose produces different blood levels in different bodies. In a trial by Andjela Drincic and colleagues, obese adults given 1,000, 5,000 or 10,000 IU daily for 21 weeks gained an average of 12.4, 27.8 and 48.1 ng/mL respectively, with wide individual variation.

The authors estimated that roughly 2.5 IU per kilogram of body weight was needed to raise 25(OH)D by 1 ng/mL.

A large observational analysis of more than 17,000 healthy volunteers reached a similar conclusion, recommending doses two to three times higher for obese people and 1.5 times higher for overweight people.

It also showed steeply diminishing returns: serum levels rose about 12 nmol/L per 1,000 IU at the low end of intake, but only about 1.1 nmol/L per 1,000 IU between 15,000 and 20,000 IU.

Anyone who stays below target on 5,000 IU is unlikely to be fixed by doubling the dose blindly. Absorption problems, adherence and a fresh blood test deserve attention first.

Absorption: The Meal Matters More Than the Clock

Vitamin D is fat-soluble, and the practical advice is to take it with food. A 2015 trial of 50 older adults found peak vitamin D3 levels were 32 percent higher after a meal containing fat than after a fat-free one.

A separate 90-day trial found no long-term difference between low-fat and high-fat meals, which suggests that an ordinary meal is enough and that engineering a high-fat breakfast around a capsule is unnecessary.

Conditions that impair fat absorption, such as celiac disease, Crohn’s disease and gallbladder problems, can blunt the response, as can the weight-loss drug orlistat and long-term corticosteroids. Anyone with these factors who is not responding to a reasonable dose has a medical question, not a supplement-shopping question.

Several add-on claims deserve skepticism. Magnesium is a genuine cofactor in vitamin D activation, but assertions that vitamin D3 supplements deplete magnesium and cause palpitations come largely from supplement-industry commentary, not controlled trials.

Vitamin K2 is often paired with D3, and a ratio of 100 mcg of K2 per 1,000 IU of D3 circulates widely, yet no official recommendation sets any ratio. Cholecalciferol (D3) is generally the preferred form over ergocalciferol (D2) for raising and maintaining levels.

Unit confusion also causes real errors: 40 IU equals 1 mcg, and a 25(OH)D result in ng/mL becomes nmol/L when multiplied by roughly 2.5.

When a Blood Test Should Change the Dose

The guideline discourages routine testing in the general population, and that is sensible for healthy adults eating a normal diet.

Testing earns its cost in specific situations: documented deficiency, obesity, fat malabsorption, kidney disease, and long-term use of 4,000 IU or more. In these cases, a 25(OH)D result a few months after starting or changing a dose turns guesswork into measurement.

Anyone with chronic kidney disease should have dosing directed by a clinician, given the case history above.

A Four-Question Dosing Check

Before choosing a dose, four questions do most of the work. The first is purpose: prevention in a healthy adult, a guideline-recognized group, or treatment of documented deficiency each justifies different amounts.

The second is baseline: a measured level, or at least a clear reason to suspect a low one, such as limited sun exposure, dark skin at high latitude or a restricted diet.

The third is body size, since the same capsule produces a smaller rise in a person with a higher BMI. The fourth is delivery: a daily dose of D3 with a normal meal, rather than a periodic megadose taken on an empty stomach.

Most people who fail this check are not taking too little. They are taking an arbitrary amount, on an arbitrary schedule, for a benefit the best trials have not confirmed in people who were already sufficient.

A dose chosen from a blood result, a body weight and a stated purpose will almost always outperform a number chosen from a label.

What People Ask